Centuple Global Ltd Falls 4.75%: 2 Key Factors Behind the Weekly Decline
2026-11-21 17:04:59Key Events This Week 16 Nov: Stock opens at Rs.32.62, down 3.80% amid downgrade news 17 Nov: Upgrade in valuation grade to Attractive; price rises 4.84% to Rs.34.20 18 Nov: Price retreats 4.53% to Rs.32.65 following sector challenges 19 Nov: Strong volume surge; price rebounds 4.10% to Rs.33.99 20 Nov: Week closes lower at Rs.32.30, down 4.97% on moderate volume Week Open<div class...
Read More
Centuple Global Ltd Valuation Shifts Signal Renewed Price Attractiveness Amid Sector Challenges
2026-11-18 08:02:44Centuple Global Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its valuation parameters improve from very attractive to attractive, signalling a potential shift in price attractiveness despite ongoing challenges in its financial performance and market returns.
Read More
Centuple Global Ltd Downgraded to Strong Sell Amid Flat Financials and Weak Fundamentals
2026-11-17 08:30:10Centuple Global Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has been downgraded from a Sell to a Strong Sell rating following a comprehensive reassessment of its quality, valuation, financial trend, and technical parameters. The downgrade reflects a combination of flat recent financial performance, deteriorating fundamentals, and subdued market momentum, signalling caution for investors amid challenging conditions.
Read More
Centuple Global Ltd Valuation Shifts Signal Renewed Price Attractiveness Amid Sector Challenges
2026-10-05 08:01:29Centuple Global Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen a notable shift in its valuation parameters, moving from an attractive to a very attractive rating. Despite a challenging year marked by significant share price declines and underperformance relative to the Sensex, the company’s improved price-to-earnings and price-to-book ratios suggest a potential revaluation opportunity for investors willing to navigate sector headwinds.
Read MoreCentuple Global Ltd Falls 14.54%: 4 Key Factors Driving the Sharp Decline
2026-09-19 17:02:29Key Events This Week 15 Sep: Stock opens at Rs.34.87, down 0.37% amid broader market weakness 16 Sep: Valuation shifts signal changing market perception; stock drops 4.99% 17 Sep: Falls to 52-week low of Rs.31.48, down 4.98% 18 Sep: Downgraded to Strong Sell; hits new 52-week low of Rs.29.91 Week OpenRs.35.00 Week Close</di...
Read More
Centuple Global Ltd Downgraded to Strong Sell Amid Technical and Financial Concerns
2026-09-18 08:07:51Centuple Global Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Sell to Strong Sell as of 17 September 2026. This shift reflects deteriorating technical indicators, modest valuation improvements, weak financial trends, and a challenging market environment that has weighed heavily on the stock’s performance.
Read More
Centuple Global Ltd Falls to 52-Week Low of Rs 31.48 as Sell-Off Deepens
2026-09-17 09:39:09For the fourth consecutive session, Centuple Global Ltd has seen its share price decline, culminating in a fresh 52-week low of Rs 31.48 on 17 Sep 2026. This marks a 12.53% drop over the last four days, underscoring persistent selling pressure despite some positive financial indicators.
Read More
Centuple Global Ltd Valuation Shifts Signal Changing Market Perception
2026-09-16 08:00:41Centuple Global Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen a notable shift in its valuation parameters, moving from a very attractive to an attractive rating. Despite a challenging market environment and significant underperformance relative to the Sensex, the company’s current price-to-earnings (P/E) and price-to-book value (P/BV) ratios suggest a more compelling price entry point for investors seeking exposure to this segment.
Read MoreAnnouncement under Regulation 30 (LODR)-Newspaper Publication
17-Nov-2026 | Source : BSESubmission of Copy of Publiaction of Advertisement of Unaudited Standalone Financial Results.
Board Meeting Outcome for Board Meeting Outcome For The Meeting Of The Board Of Directors
13-Nov-2026 | Source : BSEOutcome of the Meeting of the Board of Directors for approval of Unaudited Standalone Financial Results
Shareholder Meeting / Postal Ballot-Scrutinizer"s Report
13-Nov-2026 | Source : BSEScrutinizer Report - Postal Ballot
Corporate Actions
No Upcoming Board Meetings
No Dividend history available
No Splits history available
No Bonus history available
No Rights history available
